DDInter1534 DDInter734
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora. The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.
Propafenone {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Propafenone {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Propafenone {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Fidaxomicin
Propafenone {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Propafenone {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Propafenone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Propafenone (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Propafenone may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Fidaxomicin (Compound)
Propafenone may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fidaxomicin (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Fidaxomicin (Compound)
Propafenone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)